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2Abstract
Background: 22q11.2 Deletion Syndrome (22q11.2DS) is one of the strongest known 
genetic risk factors for developing schizophrenia. Individuals with 22q11.2DS have high 
rates of neurodevelopmental disorders in childhood, while in adulthood ~25% develop 
schizophrenia. Similar to the general population, high rates of comorbidity are common
in 22q11.2DS. Employing a dimensional approach where psychopathology is examined 
at the symptom-level as complementary to diagnostic categories in a population at such 
high genetic risk for schizophrenia can help gain a better understanding of how 
psychopathology is structured as well as its genetic underpinnings. This is the first study 
to examine the dimensional structure of a wide spectrum of psychopathology in the 
context of a homogeneous genetic etiology like 22q11.2DS. Methods: We evaluated
331 individuals with 22q11.2DS, mean age (SD)= 16.9(8.7); 51% males, who underwent 
prospective comprehensive phenotyping. We sought to replicate previous findings by 
examining a bi-factor model that derives a general factor of psychopathology in addition 
to more specific dimensions of psychopathology (i.e., internalizing, externalizing and 
thought disorder). Results: Psychopathology in 22q11.2DS was divided into one 
‘general psychopathology’ factor and four specific dimensions (i.e., ‘anxiety’, ‘mood’, 
‘ADHD’ and ‘psychosis’). The ‘psychosis’ symptoms loaded strongly on the ‘general 
psychopathology’ factor. Conclusions: The similarity of the symptom structure of 
psychopathology between 22q11.2DS and community and clinical populations without 
the deletion indicate that 22q11.2DS can provide a model to explore alternative 
approaches to our current nosology. Our findings add to a growing literature indicating 
the need to reorganize current diagnostic classification systems. 
Keywords: 22q11.2DS, psychopathology, schizophrenia, symptoms
3Introduction
22q11.2 Deletion syndrome (22q11.2DS) is caused by a submicroscopic deletion in the 
long arm of chromosome 22 and has been associated with multiple diverse clinical 
manifestations (Shprintzen, 2008) including congenital immunodeficiency, heart defects, 
velopharyngeal insufficiency and cleft palate (Bassett et al., 2011). 22q11.2DS is among
the strongest known genetic risk factors for developing schizophrenia. By adulthood, 
~25% of patients with the deletion are diagnosed with schizophrenia, while elevated 
rates of neurodevelopmental disorders have been reported in childhood (Bearden et al., 
2001; Hooper et al., 2013; Niarchou et al., 2014b; Tang, S.X. et al., 2014; Vorstman et 
al., 2006). Studies to date have indicated that the schizophrenia phenotype in 
individuals with 22q11.2DS is similar to non-deleted people with schizophrenia (Bassett 
et al., 2003; Niarchou et al., 2014a; Tang et al., 2016). Hence, examining this relatively 
homogenous group with the same genetic syndrome can provide clues on a potential 
pathway to schizophrenia that could be of relevance to the general population by
disentangling the complexity of genotype-phenotype relationships and disease 
mechanisms (Owen et al., 2010).
Similar to clinical and community populations (Andrews et al., 2002; Kessler et al., 
2005; Krueger and Markon, 2006), high rates of comorbidity are common for 
22q11.2DS. For example, 37.5% of children with 22q11.2DS with Attention Deficit 
Hyperactivity Disorder (ADHD) also had at least one anxiety disorder, 37.5% also had 
Oppositional Defiant Disorder (ODD) and 41% screened positive for autism (Niarchou et 
al., 2014b). It is unknown whether the high overlap among psychiatric disorders is due 
to shared etiology or due to limitations of diagnostic nomenclature in describing disease 
processes (Bukstein et al., 1989). Examining disorders independently limits our capacity 
to understand the shared risk factors and etiological mechanisms that underlie these 
conditions in the general population. Factor-analytic approaches have been developed 
to better capture the common characteristics of these disorders. 
Studies in clinical and community samples have examined the symptom-level structure 
of psychopathology and have provided conceptual insights into psychopathology
4(Carragher et al., 2015). In general, they support the existence of two dimensions: the 
internalizing (including anxiety and depression symptoms) and externalizing (including 
antisocial, hyperactive and aggressive symptoms) dimensions of psychopathology. This 
finding has been replicated across different ages (Eaton et al., 2011), ethnicities (Eaton 
et al., 2013) and cultures (Calkins et al., 2015; Kessler et al., 2011; Krueger et al., 2003; 
Slade and Watson, 2006; Vollebergh et al., 2001). Studies that have also assessed 
psychosis have demonstrated an additional thought disorder dimension which is formed 
by schizophrenia-spectrum disorders or symptoms (Caspi et al., 2013; Kotov et al., 
2011; Markon, 2010; Wright et al., 2013). Recently, a general psychopathology factor
has been reported (Calkins et al., 2015; Caspi et al., 2013; Lahey et al., 2012), which 
explains the common variance across individual psychiatric disorder symptoms and 
represents individuals’ general propensity to endorse such symptoms (Caspi et al., 
2013).
Our aim was to employ a dimensional approach where psychopathology is examined at 
the symptom-level rather than in diagnostic categories in a population at high genetic 
risk for schizophrenia. This can improve understanding of how psychopathology is 
structured as well as its genetic underpinnings. Examining the extent to which the 
dimensions of psychopathology in 22q11.2DS resemble those seen in the general 
population can provide insight into the degree to which 22q11.2 can provide a model to 
explore alternative approaches to our current nosology. This is the first study to 
examine the dimensional structure of a broad range of psychopathology in 22q11.2DS. 
Findings are based on one of the world’s largest samples of 22q11.2DS individuals who 
underwent prospective comprehensive phenotyping at a single site. We sought to 
replicate previous findings by examining a bi-factor model that derives a general factor 
of psychopathology in addition to more specific dimensions of psychopathology (i.e., 
internalizing, externalizing and thought disorder) (Calkins et al., 2015; Caspi et al., 
2013; Lahey et al., 2012). We hypothesized that the symptom-level structure of 
psychopathology would be similar to that reported previously in samples without the 
deletion. 
5Materials and methods
Sample
Three hundred and thirty-one individuals with 22q11.2DS ((51% males, mean age 
(SD)= 16.9(8.7), age range=8 to 52 years) took part in the study. The majority of the 
sample were Caucasians (86%), there were also 9% African Americans, 1% Asian and 
4% mixed ethnicities. The sample has been previously described (Gur et al., 2014; 
Tang, S et al., 2014). The rates of the endorsements of individual items are detailed in 
Table 1. Individuals with 22q11.2DS were referred mainly through the ‘22Q and You 
Center’ at the Children’s Hospital of Philadelphia as well as from social networks. 
Presence of the deletion was confirmed for all individuals using multiplex ligation-
dependent probe amplification (Jalali et al., 2008). Exclusion criteria included inability to 
consent and moderate to severe intellectual disability based on clinical evaluation and 
IQ testing or estimated from the reading segment of the Wide Range Achievement Test 
4 (WRAT4; estimated IQ<70) (Wilkinson and Robertson, 2006). 
The study was approved by the Institutional Review Boards of the University of 
Pennsylvania and the Children’s Hospital of Philadelphia. Informed consent/assent was 
obtained from adult participants and from caretakers of younger participants with their 
assent.
Measures
Psychopathology
For the current report, psychopathology was examined at the symptom-level rather than 
in diagnostic-categories, thus avoiding the common limitation of disease categorization 
and improving statistical power (Chmura Kraemer et al., 2004). Symptoms assessed 
were derived from interview schedules based on lifetime history of DSM-IV-TR criteria 
for ADHD, Major Depressive Disorder (MDD), Bipolar Disorder (BPD), Generalized 
Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD) and Obsessive Compulsive 
Disorder (OCD) using a modified and locally computerized Schedule for Affective 
6Disorders and Schizophrenia for School-Age Children (K-SADS (Kaufman et al., 1997)). 
Psychosis spectrum symptoms during the preceding 6 months were assessed using the 
Structured Interview for Prodromal Syndromes (SIPS; (Miller et al., 2003)) while the 
Structured Clinical Interview for DSM-IV (SCID, modules C and D; (First and Gibbon, 
2004)) was also applied for psychotic and mood differential diagnoses. Embedded 
questions assessed history of suicidal ideation/behavior and self-harm. Interviewers 
were experienced and trained clinical assessors who were supervised by clinical 
investigators. The primary caregiver was interviewed about the proband while proband 
interviews were also administered to participants ³11 years. Participants and collaterals 
were also clinically interviewed by an experienced investigator.
As can be seen in Table 1, the K-SADS item pool covers many DSM-IV-TR symptoms 
of several of the disorders (e.g., ADHD), but comparably fewer for some disorders (e.g., 
MDD). We selected the stem questions (i.e., screen-level questions) of these 
disorders. This was because administration of the K-SADS involved skip logic  i.e., if 
someone did not endorse a sub-set of screening items about a disorder, s/he was not 
asked the remaining items about that disorder. This resulted in a substantial amount of 
missing data, and we therefore used only screening items in this analysis. However, 
although we kept only the screening items, these had good positive predictive values for 
clinical diagnosis. For example, of those screening positive for depression, 23% were 
diagnosed MDD, of those who screened positive for any anxiety disorder, 50% were 
diagnosed with an anxiety disorder. Similarly, of those screening positive for ADHD, 
50% where diagnosed with ADHD. In contrast, among those screening positive for 
bipolar, 2% were diagnosed with bipolar disorder. The low positive predictive value for 
bipolar disorder may be explained in part by the rarity of bipolar disorder in this sample.
Some of the K-SADS questions were combined prior to analysis because they 
assessed the same symptom. In this case, if the subjects endorsed either/or in any of 
them, this was counted as a yes. For a list of symptoms assessed please see table 1.
All study variables were dichotomous (0=no, 1=yes), where SIPS subscales were coded 
as 1 for clinically significant (rating of 3-6) or 0 for non-significant levels of endorsement 
(rating of 0-2). 
7Data analysis
We first conducted exploratory factor analyses (EFAs) on the symptom-level data.  
Unidimensional, 2-, 3-, and 4-factor solutions were extracted using the Bayes estimator
(Muthén and Asparouhov, 2012) in Mplus (Muthén and Muthén, 1998-2011) and rotated 
using oblimin.  The Bayes estimator was chosen due to several advantages over 
conventional estimators (Depaoli and van de Schoot, 2015; van de Schoot and Depaoli, 
2014), such as substantially reduced vulnerability to Heywood cases (Heywood, 1931)
and non-positive-definite residual correlation matrices.
Of the four EFAs described above, the four-factor solution was determined to be optimal 
based on examination of the scree plot (Cattell, 1966), model fit and interpretability of 
the solution. The item-factor assignments from the four-factor solution were then used 
to build and perform a confirmatory factor analysis (CFA) bifactor model.  Bifactor 
modeling (Reise, 2012; Reise et al., 2010) involves allowing each item to load on 
exactly two factors, one specific factor (e.g., psychosis) and one general factor 
comprising all items.  A key benefit of bifactor modeling is that accounting for the 
general factor allows one to model the specific factors orthogonally, because the 
correlations among the sub-factors (e.g., between psychosis and depression) are 
accounted for by the general factor and therefore do not need to be modeled.  See 
(Reise et al., 2010): Figure 1 for conceptual visualization of the bifactor model 
compared to other models.
To assess the concurrent validity of the latent dimensions in the measurement model 
described above, age and sex were included in the model.  That is, it was a multiple-
indicators multiple-causes (MIMIC) model (Jöreskog and Goldberger, 1975) in which the 
latent variables were indicated by their respective items, and individual differences on 
the latent variables were “caused” by age and sex.  A benefit of estimating the 
measurement model and the effects of interest (age and sex) simultaneously is that it 
obviates the need to calculate factor scores and therefore avoids potential problems 
therein (e.g., indeterminacy; see (Grice, 2001)).  Bayes estimation was used (as in the 
EFA), and model fit was judged via posterior predictive checking (Gelman et al., 1996).
8Results
Exploratory factor analysis (EFA)
The fit of the unidimensional, 2- and 3-factor models was poor (posterior predictive 
value for the model p<0.001, p<0.01 and p<0.05 respectively, 95% Confidence Interval 
for the difference between the observed and the replicated chi-squared values 479.69 to 
858.91; 93.61 to 479.30 and 13067 to 408.448 respectively). The 4-factor solution fit 
was good (p=0.09, 95% CI: 63.81 to 326.91). 
It should be noted that in an EFA the null hypothesis is that the model has good fit (i.e., 
there is no difference between the observed data and our hypothesized model). 
Consequently, a significant p-value suggests that the null hypothesis should be rejected 
because the hypothesized model does not adequately explain the covariances among 
items in the sample. This is why the 4-factor solution was selected. 
The 4-factor solution extracted the following items (Table 1). The 1st factor (anxiety), 
included all the items from the GAD and SAD sections, as well as one symptom from 
the OCD section (OCD3- feel the need to do things just right), and the SIPS ‘impaired 
tolerance to normal stress’ general symptom item (G4). The 2nd factor (ADHD), included 
all the ADHD items, plus the ‘trouble with focus and attention’ disorganization symptom
(D3) and ‘motor disturbances’ general symptom from the SIPS (G3). The 3rd factor 
(mood) included all the items from the OCD, MDD and BPD and suicide sections as well 
as the ‘dysphoric mood’ general symptom from the SIPS (G2). Finally, the 4th factor 
(psychosis), included the remaining SIPS positive, negative, disorganized and general
symptoms.
We selected the 4- factor solution for our confirmatory analyses because the fit of the 4-
factor solution was better, the scree plot identified 4 factors and the interpretation of the 
factors was more plausible. For the unidimensional, 2- and 3- factor solutions see 
Supplementary table 1. 
Confirmatory Bifactor Analysis
Table 2 and Figure 1 show the 4- factor bifactor solution including sex and age as 
covariates. The fit of the model was good (posterior predictive p-value=0.06; 95% 
9confidence interval for the difference between the observed and the replicated chi-
squared values -29.59 to 332.23).
The general psychopathology factor was strong (mean loading=0.49). The items loading 
highest on the general factor were BPD1 (increased motor activity, loading=0.89), BPD2 
(increased energy, loading=0.76) and BPD5 (elevated mood, loading=0.75) while the 
items with the lowest loadings were SAD2 (wanting to avoid being away from 
attachment figures, loading= 0.19), ADHD14 (difficulty with quiet activities, 
loading=0.22) and MDD1 (sad or depressed most of the time, mean loading=0.25). The 
items that composed the psychosis factor had the highest mean loading (0.58) on the 
general factor compared to the items of the other factors (ADHD – mean loading=0.42; 
anxiety=0.45; mood=0.50). 
After controlling for the general factor, the mean loading of the items on the psychosis 
factor was reduced from 0.66 to 0.48, indicating that they are essential to the general 
psychopathology factor. No other differences were noted for the other factors.
There were also strong associations with the sex and age of the participants. Being 
male was associated with higher symptoms of ‘ADHD.’ ‘Anxiety’ and ‘ADHD’ were
reduced with age, while ‘mood’ symptoms were associated with increased age.  
10
Discussion
Overall summary
This is the first study to examine the dimensional structure of a wide spectrum of 
psychopathology in the context of a homogeneous genetic etiology like 22q11.2DS. Our 
findings indicate that psychopathology in 22q11.2DS is divided into a strong ‘general 
psychopathology’ factor and four additional factors; ‘mood’, ‘anxiety’, ‘psychosis’ and 
‘ADHD’. The strongest loadings on the ‘general psychopathology’ factor were from the 
psychosis symptoms, indicating that psychosis plays a major role in the propensity for 
psychopathology in 22q11.2DS. When controlling for the ‘general psychopathology’ 
factor the loadings of the symptoms remained high. Males were more likely to 
experience ‘ADHD’ symptoms while younger age was associated with ‘ADHD’ and 
‘anxiety’ and older age was associated with ‘mood’.
The dimensional structure of psychopathology in 22q11.2DS
Our hypothesis was supported. In accordance with previous studies in the general 
population, the dimensions of internalizing (‘anxiety’ and ‘mood’), externalizing (‘ADHD’)
and thought disorder (‘psychosis’) emerged, as well as the dimension of ‘general 
psychopathology’ (Carragher et al., 2014; Krueger et al., 2003; Lahey et al., 2015; 
Markon, 2010; Slade and Watson, 2006; Stochl et al., 2015; Vollebergh et al., 2001). 
The internalizing dimension was further divided into ‘anxiety’ and ‘mood’. The ‘anxiety’ 
dimension included symptoms related to stress (i.e., symptoms of GAD, SAD, OCD and 
the ‘impaired tolerance to normal stress’ symptom from the SIPS) while the ‘mood’
dimension included symptoms related to mood (i.e., symptoms of MDD, BPD, Suicide, 
OCD and the ‘dysphoric mood’ symptoms from the SIPS). These results are consistent 
with previous studies (Krueger, 1999; Krueger and Markon, 2006; Slade and Watson, 
2006). However, MDD in previous studies was clustered with anxiety rather than with 
bipolar. Our study does not provide evidence for dissolving the class of mood disorders 
as has been previously suggested (Goldberg et al., 2009; Kotov et al., 2011). This 
difference could reflect our evaluation of symptoms rather than diagnoses, but it could 
also indicate a pathway that is more unique to individuals with the deletion. Interestingly, 
the ‘increased motor activity’ symptom had the highest loading on the general 
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psychopathology factor. Indeed, motor deficits are common in 22q11.2DS and there is 
also evidence suggesting that 22q11.2DS is a risk factor for early-onset Parkinson 
disease (Butcher et al., 2013). Further studies to examine potential associations of 
motor deficits with psychopathology are warranted.
Consistent with previous reports (Calkins et al., 2015; Caspi et al., 2013; Lahey et al., 
2012), our findings indicate the existence of a strong ‘general psychopathology’ factor.
This factor has been interpreted as the individuals’ propensity to experience
psychopathology (Caspi et al., 2013). Previous studies examining the symptom 
structure of the SIPS have demonstrated that positive and negative symptoms load on 
two different factors in both people with schizophrenia (Blanchard and Cohen, 2006)
and individuals with 22q11.2DS (Tang, Sunny  et al., 2014). However, these studies did 
not examine the SIPS together with other psychopathology domains to understand how 
and whether SIPS symptoms load on a ‘general psychopathology’ factor. Our study 
indicates that positive symptoms and negative symptoms loaded on both the ‘general 
psychopathology’ and the ‘psychosis’ factor in 22q11.2DS. It remains to be seen 
whether these results are replicated in other genetic syndromes and in other 
populations at high-risk for schizophrenia.
Theoretical and clinical implications
Our findings indicate that current diagnostic classification systems are not adequately 
capturing the highly correlated nature of psychopathology in 22q11.2DS. The lack of 
associations between biomarkers and specific risk factors with independent psychiatric 
disorders in 22q11.2DS as well as in the non-22q11.2DS populations (Caspi et al., 
2013) might partly stem from the effect of the ‘general psychopathology’ factor.
Updating psychiatric nosology to also reflect the underlying dimensional structure of 
psychopathology may help advance our mechanistic understanding of psychiatric 
disorders (Stochl et al., 2015). 
Research on the clinical utility of dimensions is still in its early phases (Carragher et al., 
2015). However, our findings support a growing body of evidence indicating that 
obtaining a better understanding of the underlying liabilities of psychiatric disorders 
using these dimensional approaches can help direct treatment options (Carragher et al., 
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2015). Moreover, our findings are further evidence that psychiatric assessments of 
individuals with 22q11.2DS should not be limited to a single disorder. 
Strengths and limitations
The rarity of 22q11.2DS hinders recruitment of large samples with detailed phenotyping. 
This is therefore the first study sufficiently powered to examine the dimensional
structure of a broad range of psychopathology in 22q11.2DS. Our findings can inform 
future genetic studies in 22q11.2DS. Examining the genetic underpinnings of the 
dimensions of psychopathology can provide insights on shared risk and etiological 
mechanisms that overlap across different psychiatric disorders. Moreover, 
demonstration of a dimensional structure of psychopathology in 22q11.2DS that is 
similar to the structures demonstrated in other populations provides evidence that 
clinical psychological measurement can be conducted in the 22q11.2DS population with 
minimal (if any) caveats about possible qualitative differences between the nature of 
psychopathology in 22q11.2DS and other populations.  An additional strength is the use 
of Bayesian estimation that is advantageous over conventional estimators (Depaoli and 
van de Schoot, 2015; van de Schoot and Depaoli, 2014). Given that this study is the 
first in this population, replication in other datasets is needed before these associations 
are considered reliable. Due to time constraints, one limitation of the study is the lack of 
assessments for other disorders (e.g., Social Phobia, Specific Phobia, Autism Spectrum 
Disorder and antisocial behavior), which could potentially alter the structure. Another 
limitation of our analytical approach is that we only included stem questions and not all 
the symptoms that might reflect a disorder including associated symptoms and distress
or impairment.  Finally, we report cross-sectional data and the age range of our 
population is relatively wide. It is possible that the dimensional structure of 
psychopathology differs across age groups. Future studies are needed to examine 
dimensionally the longitudinal course of comprehensive psychopathology domains. 
Conclusions
We examined the dimensional structure of psychopathology in individuals with 
22q11.2DS. Psychopathology in 22q11.2DS was divided into one ‘general 
psychopathology’ factor and four specific dimensions (i.e., ‘anxiety’, ‘mood’, ‘ADHD’ and 
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‘psychosis’). The ‘psychosis’ symptoms loaded strongly on the ‘general 
psychopathology’ factor. The similarity of the symptom structure of psychopathology 
between 22q11.2DS and community and clinical populations without the deletion 
indicate that 22q11.2DS can provide a model to explore alternative approaches to our 
current nosology. Our findings add to an expanding literature indicating the need to 
reorganize current diagnostic classification systems. Further studies in other high risk 
populations are needed to replicate and establish the generalizability of these findings. 
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Table 1. 4- factor solution using Bayes Estimation
Item description Item Proportions 
endorsed
4-factor
F1 F2 F3 F4
Worrier GAD1 0.64 0.87 -0.01 0.13 0.06
Worrying more than most people GAD2 0.57 0.85 -0.02 0.11 0.07
Worries about being away from 
attachment figures
SAD1 0.20 0.81 -0.12 -0.05 0.18
Wanting to avoid being away from 
attachment figures
SAD2 0.23 0.91 -0.05 -0.03 0.05
Upset/worried in anticipation of being 
away from attachment figures
SAD3 0.23 0.88 -0.04 0.03 0.08
Separation dreams SAD4 0.09 0.45 0.26 0.24 0.22
Fear of being alone SAD5 0.33 0.69 0.13 -0.17 0.03
Obsessions (i.e., bothersome, 
intrusive, and repetitive thoughts)
OCD1 0.45 0.05 -0.02 0.44 0.09
Compulsions (i.e., repetitive and 
intrusive behaviors)
OCD2 0.42 0.30 0.01 0.30 -0.04
Feel the need to do things just right OCD3 0.16 0.36 0.12 0.35 -0.14
Frequent trouble paying attention to 
school/work/chores
ADHD1 0.68 -0.07 0.96 -0.10 0.07
Frequent trouble paying attention to 
enjoyable activities
ADHD2 0.30 -0.09 0.78 0.08 0.24
Difficulty paying attention to 
instructions
ADHD3 0.56 0.07 0.83 -0.14 0.22
Difficulty sustaining attention to 
activities requiring mental effort
ADHD4 0.59 -0.05 0.83 -0.10 0.24
Often losing things/ making careless 
mistakes
ADHD5 0.57 -0.10 0.78 0.01 0.04
Difficulty planning/organizing ADHD6 0.63 -0.05 0.83 0.02 0.19
Daydreaming/trouble listening ADHD7 0.55 -0.10 0.78 0.13 0.06
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Often forgetting ADHD8 0.48 0.06 0.80 0.06 0.08
Often distracted ADHD9 0.62 -0.02 0.92 -0.09 0.07
Difficulty remaining still ADHD10 0.41 0.25 0.76 0.19 -0.19
Fidgety ADHD11 0.49 0.19 0.81 -0.07 -0.31
Always on the go ADHD12 0.33 -0.05 0.85 0.24 -0.21
Climbing on things/ running around 
when it’s not appropriate
ADHD13 0.28 -0.14 0.92 0.10 0.09
Difficulty with quiet activities ADHD14 0.23 0.14 0.83 -0.03 -0.15
Extremely talkative ADHD15 0.32 0.13 0.77 0.03 -0.18
Blurting out answers/interrupting 
people when they are talking
ADHD16 0.40 0.10 0.70 0.04 0.06
Trouble waiting for turn ADHD17 0.46 0.04 0.75 -0.08 0.10
Sad or depressed most of the time MDD1 0.30 -0.03 -0.16 0.87 0.11
Cried a lot, or felt like crying MDD2 0.23 0.08 0.02 0.76 -0.04
Grouchy, irritable or in a bad mood 
most of the time
MDD3 0.34 -0.06 -0.07 0.86 0.07
Loss of interest MDD4 0.21 -0.09 -0.14 0.82 0.21
Depressive mood change observable 
by others
MDD5 0.64 0.13 -0.13 0.72 0.04
Increased motor activity BPD1 0.09 0.26 0.40 0.58 0.07
Increased energy BPD2 0.08 0.13 0.36 0.60 0.02
Decreased need for sleep BPD3 0.07 0.08 0.40 0.55 -0.03
Pressured speech/flight of ideas BPD4 0.10 0.16 0.24 0.66 -0.02
Elevated mood BPD5 0.04 0.24 0.31 0.60 0.14
Feeling like they could do almost 
anything
BPD6 0.05 0.30 0.26 0.69 -0.17
Irritable mood BPD7 0.17 0.11 0.12 0.71 -0.02
Unusual thought content/delusional 
ideas
P1 0.21 0.13 0.00 0.17 0.77
Suspiciousness/persecutory ideas P2 0.22 0.27 -0.02 0.24 0.67
Grandiose ideas P3 0.07 0.29 -0.02 0.06 0.65
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Perceptual 
abnormalities/hallucinations
P4 0.25 -0.02 -0.11 0.15 0.71
Disorganized communication P5 0.18 0.16 0.19 -0.02 0.64
Social anhedonia N1 0.21 0.11 0.06 0.03 0.66
Avolition N2 0.32 0.08 0.16 -0.08 0.72
Expression of emotion N3 0.19 -0.05 0.05 0.16 0.64
Experience of emotions and self N4 0.05 -0.07 0.07 0.27 0.62
Ideational richness N5 0.54 0.14 0.17 -0.23 0.61
Occupational functioning N6 0.24 -0.06 0.20 0.12 0.79
Odd behavior or appearance D1 0.13 0.31 0.11 0.05 0.68
Bizarre thinking D2 0.09 0.08 0.09 0.12 0.83
Trouble with focus and attention D3 0.43 0.07 0.74 -0.09 0.25
Impairment in personal hygiene D4 0.13 0.17 0.27 0.04 0.51
Sleep disturbance G1 0.28 0.21 0.02 0.24 0.44
Dysphoric mood G2 0.22 -0.01 -0.04 0.57 0.42
Motor disturbances G3 0.06 0.09 0.36 0.19 0.16
Impaired tolerance to normal stress G4 0.32 0.46 0.16 0.06 0.43
Passive thoughts about death/dying SUI1 0.19 0.10 -0.09 0.69 0.15
Suicidal thoughts SUI2 0.10 -0.09 -0.03 0.72 0.34
Abbreviations: GAD– Generalized Anxiety Disorder, SAD- Separation Anxiety Disorder, OCD-
Obsessive Compulsive Disorder, ADHD– Attention Deficit Hyperactivity Disorder, MDD- Major 
Depressive Disorder, BPD- Bipolar Disorder, P- Positive symptoms, N-Negative symptoms, D-
Disorganization symptoms, G- General symptoms, SUI- Suicide
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Table 2. Standardized coefficients and significance levels for confirmatory factor analysis including external effects of 
interest (MIMIC model)
Parameter estimate
Latent variable Item Standardized
Coefficients
P
ADHD measured by ADHD1 0.75 <0.001
ADHD2 0.60 <0.001
ADHD3 0.53 <0.001
ADHD4 0.57 <0.001
ADHD5 0.56 <0.001
ADHD6 0.57 <0.001
ADHD7 0.58 <0.001
ADHD8 0.57 <0.001
ADHD9 0.70 <0.001
ADHD10 0.94 <0.001
ADHD11 0.87 <0.001
ADHD12 0.90 <0.001
ADHD13 0.92 <0.001
ADHD14 0.87 <0.001
ADHD15 0.62 <0.001
ADHD16 0.57 <0.001
ADHD17 0.63 <0.001
D3 0.55 <0.001
G3 0.26 0.02
Psychosis measured by P1 0.83 <0.001
P2 0.59 <0.001
P3 0.53 <0.001
P4 0.80 <0.001
P5 0.31 <0.001
N1 0.34 <0.001
N2 0.26 0.002
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N3 0.44 <0.001
N4 0.70 <0.001
N5 0.38 <0.001
N6 0.41 <0.001
D1 0.46 <0.001
D2 0.79 <0.001
D4 0.13 0.11
G1 0.21 0.02
Mood measured by MDD1 0.86 <0.001
MDD2 0.75 <0.001
MDD3 0.77 <0.001
MDD4 0.83 <0.001
MDD5 0.69 <0.001
BPD1 0.32 <0.001
BPD2 0.37 <0.001
BPD3 0.36 0.001
BPD4 0.39 <0.001
BPD5 0.55 <0.001
BPD6 0.62 <0.001
BPD7 0.53 <0.001
SUI1 0.62 <0.001
SUI2 0.71 <0.001
OCD1 0.39 <0.001
OCD2 0.27 0.001
G2 0.48 <0.001
Anxiety measured by GAD1 0.66 <0.001
GAD2 0.65 <0.001
SAD1 0.83 <0.001
SAD2 0.94 <0.001
SAD3 0.90 <0.001
SAD4 0.32 <0.001
19
SAD5 0.62 <0.001
OCD3 0.19 0.06
G4 0.26 <0.001
General psychopathology measured by GAD1 0.59 <0.001
GAD2 0.56 <0.001
SAD1 0.27 0.01
SAD2 0.19 0.03
SAD3 0.28 0.004
SAD4 0.74 <0.001
SAD5 0.28 0.001
OCD1 0.31 <0.001
OCD2 0.31 0.001
OCD3 0.39 0.002
ADHD1 0.50 <0.001
ADHD2 0.53 <0.001
ADHD3 0.69 <0.001
ADHD4 0.61 <0.001
ADHD5 0.45 <0.001
ADHD6 0.61 <0.001
ADHD7 0.49 <0.001
ADHD8 0.60 <0.001
ADHD9 0.54 <0.001
ADHD10 0.10 0.15
ADHD11 0.11 0.13
ADHD12 0.02 0.42
ADHD13 0.11 0.15
ADHD14 0.22 0.03
ADHD15 0.48 <0.001
ADHD16 0.47 <0.001
ADHD17 0.44 <0.001
MDD1 0.25 0.001
MDD2 0.31 0.002
20
MDD3 0.38 <0.001
MDD4 0.30 0.001
MDD5 0.32 0.02
BPD1 0.89 <0.001
BPD2 0.76 <0.001
BPD3 0.59 <0.001
BPD4 0.68 <0.001
BPD5 0.75 <0.001
BPD6 0.48 <0.001
BPD7 0.54 <0.001
P1 0.48 <0.001
P2 0.63 <0.001
P3 0.58 <0.001
P4 0.28 0.001
P5 0.71 <0.001
N1 0.62 <0.001
N2 0.71 <0.001
N3 0.51 <0.001
N4 0.37 <0.001
N5 0.46 <0.001
N6 0.74 <0.001
D1 0.72 <0.001
D2 0.53 <0.001
D3 0.60 <0.001
D4 0.74 <0.001
G1 0.60 <0.001
G2 0.62 <0.001
G3 0.44 0.001 
G4 0.74 <0.001
SUI1 0.47 <0.001
SUI2 0.50 <0.001
General psychopathology regressed on Sex -0.08 0.08
21
Age -0.09 0.11
Anxiety regressed on Sex 0.03 0.34
Age -0.13 0.05
Psychosis regressed on Age -0.07 0.21
Sex 0.12 0.07
ADHD regressed on Sex -0.11 0.02
Age -0.31 <0.001
Depression regressed on Sex 0.02 0.39
Age 0.30 <0.001
Sex correlated with Age 0.17 0.001
Abbreviations: MIMIC- multiple-indicators multiple-causes, GAD– Generalized Anxiety Disorder, SAD-
Separation Anxiety Disorder, OCD-Obsessive Compulsive Disorder, ADHD– Attention Deficit 
Hyperactivity Disorder, MDD- Major Depressive Disorder, BPD- Bipolar Disorder, P- Positive 
symptoms, N-Negative symptoms, D- Disorganization symptoms, G- General symptoms, SUI- Suicide
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